ArticleAging2014
Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.
Article in Aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 105 citations in OpenAlex.
- Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.International journal of obesity (2005) · 2017Trial
- Rapamycin Reverses the Hepatic Response to Diet-Induced Metabolic Stress That Is Amplified by Aging.Aging cell · 2026Article
- Cancer progression through the lens of age-induced metabolic reprogramming.Nature reviews. Cancer · 2025Review
- Article
- Proteomic and phosphoproteomic signatures of aging mouse liver.GeroScience · 2025Article
- Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy.World journal of gastrointestinal pathophysiology · 2024Review
- A biomarker framework for liver aging: the Aging Biomarker Consortium consensus statement.Life medicine · 2024Article
- CD36-mediated podocyte lipotoxicity promotes foot process effacement.Open medicine (Warsaw, Poland) · 2024Article
- HepaticiScience · 2023Article
- Early-life stress perturbs the epigenetics of Cd36 concurrent with adult onset of NAFLD in mice.Pediatric research · 2023Article
- Intermittent Fasting Attenuates Metabolic-Dysfunction-Associated Steatohepatitis by Enhancing the Hepatic Autophagy-Lysosome Pathway.Nutrients · 2023Article
- The Roles of Lipid Metabolism in the Pathogenesis of Chronic Diseases in the Elderly.Nutrients · 2023Review
- Gut microbiota induces hepatic steatosis by modulating the T cells balance in high fructose diet mice.Scientific reports · 2023Article
- Hepatoprotective effects of moderate-intensity interval training along with ginger juice in an old male rat model.Pflugers Archiv : European journal of physiology · 2023Article
- Improving obesity and lipid metabolism using conjugated linoleic acid.Veterinary medicine and science · 2022Article
- The role of aging in cancer.Molecular oncology · 2022Article
- Effect of dietary soybean oil inclusion on liver-related transcription factors in a pig model for metabolic diseases.Scientific reports · 2022Article
- A Transcriptomic Response toInternational journal of molecular sciences · 2022Article
- NAFLD: Mechanisms, Treatments, and Biomarkers.Biomolecules · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 5 countries.
Funding
Abstract
CD36 has been associated with obesity and diabetes in human liver diseases, however, its role in age-associated nonalcoholic fatty liver disease (NAFLD) is unknown. Therefore, liver biopsies were collected from individuals with histologically normal livers (n=30), and from patients diagnosed with simple steatosis (NAS; n=26). Patients were divided into two groups according to age and liver biopsy samples were immunostained for CD36. NAFLD parameters were examined in young (12-week) and middle-aged (52-week) C57BL/6J mice, some fed with chow-diet and some fed with low-fat (LFD; 10% kcal fat) or high-fat diet (HFD; 60% kcal fat) for 12-weeks. CD36 expression was positively associated with age in individuals with normal livers but not in NAS patients. However, CD36 was predominantly located at the plasma membrane of hepatocytes in aged NAS patients as compared to young. In chow-fed mice, aging, despite an increase in hepatic CD36 expression, was not associated with the development of NAFLD. However, middle-aged mice did exhibit the development of HFD-induced NAFLD, mediated by an increase of CD36 on the membrane. Enhanced CD36-mediated hepatic fat uptake may contribute to an accelerated progression of NAFLD in mice and humans. Therapies to prevent the increase in CD36 expression and/or CD36 from anchoring at the membrane may prevent the development of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.